Veracyte, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92337F1075
USD
33.48
0.56 (1.7%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
TransMedics Group, Inc.
AtriCure, Inc.
iRhythm Technologies, Inc.
ICU Medical, Inc.
Veracyte, Inc.
Integer Holdings Corp.
LivaNova Plc
NovoCure Ltd.
InMode Ltd.
STAAR Surgical Co.
Pacific Biosciences of California, Inc.

Why is Veracyte, Inc. ?

1
Poor Management Efficiency with a low ROE of 0.76%
  • The company has been able to generate a Return on Equity (avg) of 0.76% signifying low profitability per unit of shareholders funds
2
The company has declared Positive results for the last 11 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 108.24 MM
  • RAW MATERIAL COST(Y) Fallen by -2.41% (YoY)
  • CASH AND EQV(HY) Highest at USD 687.15 MM
3
With ROE of 4.30%, it has a attractive valuation with a 2.08 Price to Book Value
  • Over the past year, while the stock has generated a return of 4.47%, its profits have risen by 112.2% ; the PEG ratio of the company is 0.4
4
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Underperformed the market in the last 1 year
  • The stock has generated a return of 4.47% in the last 1 year, much lower than market (S&P 500) returns of 18.81%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Veracyte, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Veracyte, Inc. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Veracyte, Inc.
7.2%
1.05
55.07%
S&P 500
18.34%
0.98
19.26%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
34.45%
EBIT Growth (5y)
27.81%
EBIT to Interest (avg)
-14.55
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.23
Sales to Capital Employed (avg)
0.36
Tax Ratio
5.79%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0.63%
ROE (avg)
0.76%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
2.08
EV to EBIT
45.59
EV to EBITDA
31.39
EV to Capital Employed
2.52
EV to Sales
4.55
PEG Ratio
0.44
Dividend Yield
NA
ROCE (Latest)
5.52%
ROE (Latest)
4.30%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

12What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 108.24 MM

RAW MATERIAL COST(Y)

Fallen by -2.41% (YoY

CASH AND EQV(HY)

Highest at USD 687.15 MM

DEBT-EQUITY RATIO (HY)

Lowest at -25.92 %

DEBTORS TURNOVER RATIO(HY)

Highest at 10.25 times

NET SALES(Q)

Highest at USD 131.87 MM

OPERATING PROFIT(Q)

Highest at USD 28.38 MM

OPERATING PROFIT MARGIN(Q)

Highest at 21.52 %

NET PROFIT(Q)

Highest at USD 19.3 MM

EPS(Q)

Highest at USD 0.24

-8What is not working for the Company
NET PROFIT(HY)

At USD 3.76 MM has Grown at -82.23%

Here's what is working for Veracyte, Inc.

Operating Cash Flow
Highest at USD 108.24 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales
Highest at USD 131.87 MM
in the last five periods
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Operating Profit
Highest at USD 28.38 MM
in the last five periods
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin
Highest at 21.52 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Net Profit
Highest at USD 19.3 MM
in the last five periods
MOJO Watch
Near term Net Profit trend is positive

Net Profit (USD MM)

EPS
Highest at USD 0.24
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Cash and Eqv
Highest at USD 687.15 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -25.92 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 10.25 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -2.41% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales